Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica N Filderman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2020
Neoepitopes as Difference Makers for General Cancer Vaccines?Jessica N Filderman, Walter J Storkus
The Journal of Clinical Investigation|June 15, 2022
Finding the right help in the tumor microenvironmentJessica N Filderman, Walter J Storkus
Journal of Leukocyte Biology|July 3, 2023
Platelet STING agonism and venous thrombosis: translational implications for improved disease outcomesJessica N Filderman, Jason J Luke, Walter J Storkus
Cancers|June 2, 2021
STING Agonists as Cancer TherapeuticsAfsaneh Amouzegar, Manoj Chelvanambi, Jessica N Filderman, et al.
Frontiers in Immunology|May 31, 2021
STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure DevelopmentJessica N Filderman, Mark Appleman, Manoj Chelvanambi, et al.
Frontiers in Immunology|February 5, 2024
Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonistsJessica N Filderman, Jennifer L Taylor, Jianmin Wang, et al.
Vaccines|July 27, 2024
Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1Jennifer L Taylor, Kathleen M Kokolus, Per H Basse, et al.
Journal for Immunotherapy of Cancer|November 16, 2021
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanomaWalter J Storkus, Deena Maurer, Yan Lin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2020
Neoepitopes as Difference Makers for General Cancer Vaccines?Jessica N Filderman, Walter J Storkus
The Journal of Clinical Investigation|June 15, 2022
Finding the right help in the tumor microenvironmentJessica N Filderman, Walter J Storkus
Journal of Leukocyte Biology|July 3, 2023
Platelet STING agonism and venous thrombosis: translational implications for improved disease outcomesJessica N Filderman, Jason J Luke, Walter J Storkus
Cancers|June 2, 2021
STING Agonists as Cancer TherapeuticsAfsaneh Amouzegar, Manoj Chelvanambi, Jessica N Filderman, et al.
Frontiers in Immunology|May 31, 2021
STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure DevelopmentJessica N Filderman, Mark Appleman, Manoj Chelvanambi, et al.
Frontiers in Immunology|February 5, 2024
Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonistsJessica N Filderman, Jennifer L Taylor, Jianmin Wang, et al.
Vaccines|July 27, 2024
Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1Jennifer L Taylor, Kathleen M Kokolus, Per H Basse, et al.
Journal for Immunotherapy of Cancer|November 16, 2021
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanomaWalter J Storkus, Deena Maurer, Yan Lin, et al.
Pageof 1